Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

(2010) J. C. Soria et al.   ANNALS OF ONCOLOGY

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

(2010) M. Reck et al.   ANNALS OF ONCOLOGY

Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials

(2010) Everardo D. Saad et al.   JOURNAL OF CLINICAL ONCOLOGY

Time to Progression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-small Cell Lung Cancer

(2010) Katsuyuki Hotta et al.   Journal of Thoracic Oncology

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

(2009) Christopher G. Azzoli et al.   JOURNAL OF CLINICAL ONCOLOGY

Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival

(2009) Kristine R. Broglio et al.   JNCI-Journal of the National Cancer Institute

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

(2008) Edward S Kim et al.   LANCET